next-generation anti-TL1A mAb (Pfizer)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namenext-generation anti-TL1A mAb (Pfizer)
Drug Alias Nameanti-TL1A (Pfizer)anti-TNFSF15 mAb (Pfizer)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor superfamily member 15 inhibitors
TargetsTumor necrosis factor superfamily member 15
Therapy Area/IndicationsInflammationFibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer Inc
Inactive CompaniesN/A
Active IndicationsInflammationFibrosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A